[
    [
        {
            "time": "2023-10-18",
            "original_text": "智飞生物预防性微卡获批 结核防治矩阵再添重磅产品",
            "features": {
                "keywords": [
                    "智飞生物",
                    "预防性微卡",
                    "结核防治",
                    "重磅产品"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "智飞生物预防性微卡获批 结核防治矩阵再添重磅产品",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "西部证券维持智飞生物买入评级，新品获批事件点评：预防性微卡获批，完善公司结核产品矩阵",
            "features": {
                "keywords": [
                    "西部证券",
                    "智飞生物",
                    "买入评级",
                    "预防性微卡",
                    "结核产品矩阵"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "西部证券维持智飞生物买入评级，新品获批事件点评：预防性微卡获批，完善公司结核产品矩阵",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "智飞生物(300122.SZ)：母牛分枝杆菌疫苗(结核感染人群用)药品批准证明文件处于待领取状态",
            "features": {
                "keywords": [
                    "智飞生物",
                    "母牛分枝杆菌疫苗",
                    "结核感染",
                    "药品批准"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "智飞生物(300122.SZ)：母牛分枝杆菌疫苗(结核感染人群用)药品批准证明文件处于待领取状态",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "智飞生物大涨5.09% 成交额31.48万元",
            "features": {
                "keywords": [
                    "智飞生物",
                    "大涨",
                    "成交额"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物大涨5.09% 成交额31.48万元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 9,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "东吴证券维持智飞生物买入评级：微卡疫苗获得药监局批准，进入“代理+自主”双驱动增长新阶段",
            "features": {
                "keywords": [
                    "东吴证券",
                    "智飞生物",
                    "微卡疫苗",
                    "药监局批准",
                    "双驱动增长"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "东吴证券维持智飞生物买入评级：微卡疫苗获得药监局批准，进入“代理+自主”双驱动增长新阶段",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "直击智飞生物股东大会：董事长称新冠疫苗、HPV疫苗供不应求，强研发是必走之路",
            "features": {
                "keywords": [
                    "智飞生物",
                    "股东大会",
                    "新冠疫苗",
                    "HPV疫苗",
                    "供不应求",
                    "强研发"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "直击智飞生物股东大会：董事长称新冠疫苗、HPV疫苗供不应求，强研发是必走之路",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "减持资金主要投向生物医药领域 减持股份",
            "features": {
                "keywords": [
                    "减持资金",
                    "生物医药",
                    "减持股份"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "减持资金主要投向生物医药领域 减持股份",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        }
    ]
]